Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.62 |
| ▸ | PSEN1 | P49768 | 6/20 | 0.59 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.59 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.59 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.59 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.59 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.59 |
| ▸ | APP | P05067 | 1/20 | 0.59 |
| ▸ | BACE1 | P56817 | 3/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7799008 | 0.89 | KLK5 (0.62) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7789578 | 0.89 | KLK5 (0.62) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9016579 | 0.89 | KLK5 (0.62) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL9016587 | 0.89 | KLK5 (0.62) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7797841 | 0.89 | KLK5 (0.62) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL5371202 | 0.89 | KLK5 (0.62) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL7392856 | 0.89 | KLK5 (0.67) | KLK5PSEN1PSEN2APH1BNCSTN | |
| Oxalic Acid SCHEMBL7796361 | 0.87 | KLK5 (0.60) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL2059396 | 0.87 | KLK5 (0.58) | KLK5PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3361485 | 0.87 | KLK5 (0.63) | KLK5PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180256534-A1 | KETAMINE AND CYTOCHROME P 450 INHIBITOR COMBINATIONS | SEQUOIA PHARMACEUTICALS INC (US) | 2018-09-13 | — | — | US | disclosed |
| US-9849107-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9604952-B2 | Compositions and methods for inhibiting cytochrome P450 2D6 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160361287-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9233952-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150284352-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | SEQUOIA PHARMACEUTICALS INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-8952056-B2 | Methods for inhibiting drug degradation | SEQUOIA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140343078-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6 | SEQUOIA PHARMACEUTICALS INC (US) | 2014-11-20 | — | — | US | disclosed |
| US-8791157-B2 | 5-substituted benzofurans as inhibitors of cytochrome P450 2D6 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-8673970-B2 | HIV protease inhibitor and cytochrome p450 inhibitor combinations | SEQUOIA PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20140024671-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS INC (US) | 2014-01-23 | — | — | US | disclosed |
| US-8569364-B2 | 5-substituted benzofurans as inhibitors of cytochrome P450 2D6 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130217704-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6 | SEQUOIA PHARMACEUTICALS, INC. | 2013-08-22 | — | — | US | disclosed |
| US-8481520-B2 | Compositions and methods for inhibiting cytochrome P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120053132-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-8048871-B2 | Inhibitors that when coadministered with a drug that undergoes in vivo degradation by cytochrome P450 enzyme, improves the pharmacokinetics, bioavailability and disease treatment such as of HIV, Hepatitis C virus, diabetes, epilepsy, cancer, depression; amide or sulfonamide-functional benzofurans | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20110112137-A1 | HIV PROTEASE INHIBITOR AND CYTOCHROME P450 INHIBITOR COMBINATIONS | SEQUOIA PHARMACEUTICALS, INC. (MD) | 2011-05-12 | — | — | US | disclosed |
| US-20110098237-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | SEQUOIA PHARMACEUTICALS, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20090143408-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20080113945-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | SEQUOIA PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113945-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | KLK5 2889/4885PSEN1 950/4885PSEN2 999/4885 |
| US-20130217704-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6 | CYP2D6, CYP2A6, CYP2B6 | KLK5 2607/4885PSEN1 1880/4885PSEN2 893/4885 |
| US-20140343078-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6 | CYP2D6, CYP2A6, CYP2B6 | KLK5 2607/4885PSEN1 1880/4885PSEN2 893/4885 |
| US-20160361287-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | KLK5 2889/4885PSEN1 950/4885PSEN2 999/4885 |
| US-20110112137-A1 | HIV PROTEASE INHIBITOR AND CYTOCHROME P450 INHIBITOR COMBINATIONS | SERPINB1, CYP3A43, PREP | KLK5 755/4885PSEN1 384/4885PSEN2 696/4885 |
| US-20140024671-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | KLK5 2889/4885PSEN1 950/4885PSEN2 999/4885 |
| US-20120053132-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 | CYP3A43, CYP2E1, CYP7A1 | KLK5 2889/4885PSEN1 950/4885PSEN2 999/4885 |
| US-20180256534-A1 | KETAMINE AND CYTOCHROME P 450 INHIBITOR COMBINATIONS | CYP2E1, CYP3A43, CYP1A2 | KLK5 865/4885PSEN1 926/4885PSEN2 1093/4885 |
| US-20090143408-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 2D6 | CYP2D6, CYP2A6, CYP2B6 | KLK5 2607/4885PSEN1 1880/4885PSEN2 893/4885 |
| US-20150284352-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | CYP2E1, CYP3A43, CYP3A5 | KLK5 2590/4885PSEN1 796/4885PSEN2 733/4885 |
| US-20110098237-A1 | METHODS FOR INHIBITING DRUG DEGRADATION | CYP2E1, CYP3A43, CYP3A5 | KLK5 2590/4885PSEN1 796/4885PSEN2 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.